Home » Authors » Aaron Lorenzo

Articles by Aaron Lorenzo

Aton Ends $48.7M Series A With $13.7M Third Tranche

Jan. 9, 2003

By Aaron Lorenzo

PDL Enters Deal With MedImmune, Spells Out Development Strategy

Jan. 8, 2003

By Aaron Lorenzo

XenoPort, ALZA Form Alliance For Delivery Of Three Products

Jan. 8, 2003

By Aaron Lorenzo

PDL Enters Deal With MedImmune, Spells Out Development Strategy

Jan. 8, 2003

By Aaron Lorenzo

XenoPort, ALZA Form Alliance For Delivery Of Three Products

Jan. 8, 2003

By Aaron Lorenzo

Endo Gains Rights To Pain Drugs Through Deal With SkyePharm

Jan. 6, 2003

By Aaron Lorenzo

Raven Raises $40M To Advance Monoclonal Antibody Programs

Jan. 6, 2003

By Aaron Lorenzo

Endo Gains Rights To Pain Drugs Through Deal With SkyePharm

Jan. 6, 2003

By Aaron Lorenzo

Raven Raises $40M To Advance Monoclonal Antibody Programs

Jan. 6, 2003

By Aaron Lorenzo

Cellegy Enters Deal With PDL For Marketing Of Tostrex Gel

Jan. 3, 2003

By Aaron Lorenzo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 9, 2025
STAT6 stat sig? Kaken, J&J $1.2B-plus deal adds oomph to space
BioWorld
Kaken Pharmaceutical Co. Ltd.’s license agreement with Johnson & Johnson (J&J) for signal transducer and activator of transcription (STAT)6 inhibitor KP-723 could...
GLP-1 receptor agonists continue their global victory tour
BioWorld
2024 was another banner year for GLP-1 receptor agonists (GLP-1RAs) on multiple fronts. They continued to expand into new indications, and provide their...
AI drives financings, approvals for APAC med-tech in 2024
BioWorld MedTech
AI pulled in major financings and approvals for Asia med-techs in 2024 as Asia Pacific countries played to individual strengths to maximize AI’s applications in...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.